<bill session="111" type="h" number="3777" updated="2023-01-11T13:17:53Z">
  <state datetime="2009-10-08">REFERRED</state>
  <status>
    <introduced datetime="2009-10-08"/>
  </status>
  <introduced datetime="2009-10-08"/>
  <titles>
    <title type="display">Drug Price Competition Act of 2009</title>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act to define the term "first applicant" for purposes of filing an abbreviated application for a new drug.</title>
    <title type="short" as="introduced">Drug Price Competition Act of 2009</title>
  </titles>
  <sponsor bioguide_id="H000324"/>
  <cosponsors>
    <cosponsor bioguide_id="S000480" joined="2010-02-02"/>
    <cosponsor bioguide_id="T000074" joined="2009-10-08"/>
  </cosponsors>
  <actions>
    <action datetime="2009-10-08">
      <text>Introduced in House</text>
    </action>
    <action datetime="2009-10-08">
      <text>Sponsor introductory remarks on measure.</text>
      <reference ref="CR E2487-2488"/>
    </action>
    <action datetime="2009-10-08" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2009-10-09">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="111" type="s" number="1315" relation="identical"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Intellectual property"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2010-01-08T20:56:46Z" status="Introduced in House">Drug Price Competition Act of 2009 - Amends the Federal Food, Drug, and Cosmetic Act to expand the definition of "first applicant" under such Act to allow a generic drug manufacturer that is currently considered an applicant subsequent to a brand-name manufacturer's 180-day exclusivity period to qualify as a first applicant for purposes of filing an abbreviated application for a new drug. Requires such applicant to submit a substantially complete application that contains and lawfully maintains a certification for such drug.</summary>
</bill>
